A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Inclusion Criteria:

   - Be 18 years old at the time the informed consent form is signed

   - Have a histologically or cytologically confirmed adenocarcinoma or poorly
   differentiated carcinoma of the prostate

   - Be surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL
   (1.73 nM)

   - Experienced disease progression after having received at least 1 but no more than 2
   prior next-generation androgen receptor-targeted therapies, and 1 prior taxane-based
   chemotherapy, for castration-resistant disease

   - Have a deleterious mutation in BRCA1/2 or ATM, or molecular evidence of other
   homologous recombination deficiency

Exclusion Criteria:

   - Active second malignancy, with the exception of curatively treated non-melanoma skin
   cancer, carcinoma in situ, or superficial bladder cancer

   - Prior treatment with any PARP inhibitor, mitoxantrone, cyclophosphamide or any
   platinum-based chemotherapy

   - Symptomatic and/or untreated central nervous system metastases

   - Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would,
   in the opinion of the investigator, interfere with absorption of rucaparib